Moleculin Biotech Inc (NASDAQ: MBRX) on Monday, soared 11.67% from the previous trading day, before settling in for the closing price of $0.47. Within the past 52 weeks, MBRX’s price has moved between $0.25 and $3.65.
Annual sales at Healthcare sector company grew by 26.36% over the past five years. The company achieved an average annual earnings per share of 80.33%. With a float of $45.11 million, this company’s outstanding shares have now reached $49.50 million.
Moleculin Biotech Inc (MBRX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Moleculin Biotech Inc is 8.87%, while institutional ownership is 0.93%. The most recent insider transaction that took place on Jun 23 ’25, was worth 100,000. In this transaction Chief Financial Officer of this company bought 270,270 shares at a rate of $0.37, taking the stock ownership to the 287,587 shares. Before that another transaction happened on Jun 23 ’25, when Company’s CEO and President bought 675,675 for $0.37, making the entire transaction worth $250,000. This insider now owns 743,607 shares in total.
Moleculin Biotech Inc (MBRX) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -2.85 earnings per share (EPS) for the period falling under the consensus outlook (set at -2.44) by -0.41. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 80.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 45.64% during the next five years compared to 26.36% growth over the previous five years of trading.
Moleculin Biotech Inc (NASDAQ: MBRX) Trading Performance Indicators
Moleculin Biotech Inc (MBRX) is currently performing well based on its current performance indicators. A quick ratio of 1.15 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.59, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -1.05 in one year’s time.
Technical Analysis of Moleculin Biotech Inc (MBRX)
Moleculin Biotech Inc (NASDAQ: MBRX) saw its 5-day average volume 14.6 million, a positive change from its year-to-date volume of 4.47 million. As of the previous 9 days, the stock’s Stochastic %D was 32.00%.
During the past 100 days, Moleculin Biotech Inc’s (MBRX) raw stochastic average was set at 37.99%, which indicates a significant decrease from 44.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0547 in the past 14 days, which was lower than the 0.0611 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4566, while its 200-day Moving Average is $0.8008. Nevertheless, the first resistance level for the watch stands at $0.6189 in the near term. At $0.7181, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.8062. If the price goes on to break the first support level at $0.4316, it is likely to go to the next support level at $0.3435. The third support level lies at $0.2443 if the price breaches the second support level.
Moleculin Biotech Inc (NASDAQ: MBRX) Key Stats
Market capitalization of the company is 25.73 million based on 49,499K outstanding shares. Right now, sales total 0 K and income totals -21,760 K. The company made 0 K in profit during its latest quarter, and -7,640 K in sales during its previous quarter.
